<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03143140</url>
  </required_header>
  <id_info>
    <org_study_id>Z151100004015186</org_study_id>
    <nct_id>NCT03143140</nct_id>
  </id_info>
  <brief_title>The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma</brief_title>
  <official_title>The Clinical Value of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate a novel technique—ultrasound guided percutaneous abaltion of tumor feeding artery
      before RFA for liver malignancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma is one of the most common tumor in clinical practice. In recent
      years, various local therapies, especially radiofrequency ablation (RFA) has been proved safe
      and effective.The main limitation of RFA is that its therapeutic impact is significant
      compromised by blood flow cooling effect, especially in hypervascular HCC. Recent studies
      showed combined therapy of TACE and RFA can decrease the blood supply of tumor, increase
      ablated volume and therefore improve the outcome. However, TACE application is limited in
      patients who cannot tolerate this therapy due to the side effects of repeated TACE, poor
      liver function or previously legated hepatic artery. The present study is focus on
      &quot;difficult-to-treat&quot; HCC patients who are neither surgical candidates, nor TACE candidates.
      The investigators introduce the novel treatment mode that RFA followed ultrasound guided
      percutaneous ablation of tumur feeding arterial to treat these difficult cases and evaluate
      the clinical effect.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2014</start_date>
  <completion_date type="Anticipated">July 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>completed tumor necrosis</measure>
    <time_frame>1 month</time_frame>
    <description>Contrast enhanced CT or MRI was examed to evaluate tumor necrosis 1 month after ablation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor recurrence</measure>
    <time_frame>up to 36 months</time_frame>
    <description>tumor recurrence around the ablation zone</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>PAFA and tumor ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>first percutaneous frequency ablation of tumor feeding artery and then ablation of tumor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tumor ablation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ablation of tumor directly</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PAFA</intervention_name>
    <description>percutaneous ablation of tumor feeding artery</description>
    <arm_group_label>PAFA and tumor ablation</arm_group_label>
    <other_name>percutaneous ablation of tumor feeding artery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tumor ablation</intervention_name>
    <description>ablation of tumor area directly</description>
    <arm_group_label>PAFA and tumor ablation</arm_group_label>
    <arm_group_label>tumor ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. tumor number ≤3， maximum tumor size ≤5cm;

          2. accessibility of tumors via a percutaneous approach;

          3. tumor feeding artery can be detected by 3D contrast enhance ultrasound;

          4. platelet count ≥ 50,000/ml and INR &lt;1.6;

          5. life expectancy more than 6 months

          6. Child grade A or B

        Exclusion Criteria:

          1. patients who scheduled liver transplantation

          2. with extrahepatic metastasis

          3. women during menstruation, pregnancy, child birth and baby nursing period

          4. patients with severe mental disorder

          5. cardiopulmonary failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun Yan, master</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kun Yan, master</last_name>
    <phone>8601088196910</phone>
    <email>ydbz@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhongyi Zhang, doctor</last_name>
    <phone>8601088196140</phone>
    <email>zhyibmu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kun Yan, Master</last_name>
      <phone>8601088196910</phone>
      <email>ydbz@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhongyi Zhang, Doctor</last_name>
      <phone>8601088196140</phone>
      <email>zhyibmu@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Kun Yan</investigator_full_name>
    <investigator_title>Director of ultrasonography department</investigator_title>
  </responsible_party>
  <keyword>Ablation Techniques</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

